BeiGene   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2010)

Organization Overview

First Clinical Trial
2013
NCT02610361
First Marketed Drug
2019
zanubrutinib (Brukinsa)
First NDA Approval
2019
zanubrutinib (Brukinsa)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

BeiGene | BEIGENE | Beigene (Beijing) Biotechnology Co., Ltd | BeiGene (Beijing) Co., Ltd | BeiGene, Ltd. | BeiGene (Suzhou) Co., Ltd. | BeiGene USA, Inc. | BEIGENE USA INC | Beigne